Background: Development of neutralising antibodies (NAbs) against recombinant interferon-β (IFNβ) is a significant clinical problem in the treatment of multiple sclerosis (MS). Several methods are available to assess NAbs, but there is a lack of consensus on how the different NAb titre levels interfere with the efficacy of the drug, especially in the individual patient.
Methods: NAb titres were measured with an in vitro MxA induction assay and the in vivo IFNβ response was assessed by measuring MxA mRNA expression using real-time PCR.
Results: We identified titre levels of NAbs at which the IFNβ biological activity was reduced or abrogated. Patients with NAb titres of up to 150 TRU/ml (ten times reduction units per ml) still had retained IFNβ bioactivity, whereas greatly reduced levels of IFNβ bioactivity were found in patients with NAbs of 150–600 TRU/ml. Titres above 600 TRU/ml were associated with loss of IFNβ bioactivity. Similar results were obtained when TRAIL mRNA was used as a marker of the in vivo response to IFNβ.
Conclusion: There is a stepwise loss of IFNβ bioactivity with increasing NAb titres and it is possible to identify functionally critical NAb titre levels that are useful to support treatment decisions at the individual patient level.
Statistics from Altmetric.com
Funding: This study was supported by an unrestricted research grant from Biogen Idec, Inc., Schering Nordiska AB, Sweden and the European Commission (NABINMS project, 018926; LSHB-CT-2005-0189)
Competing interests: None declared.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.